Avirmax Biopharma Inc
Avirmax is a biopharmaceutical company focused on innovation and development of genetic medicines, particularly AAV-mediated biotherapeutics, to treat chronic and degenerated ocular diseases. The company aims to deliver safe, effective, durable, affordable, and accessible treatments to preserve patients' vision. It operates through its divisions Avirmax Biopharma and Avirmax CMC, providing services from DNA sequences to final gene therapy products, and specializing in bioprocess development and manufacturing of rAAV vectors.
Industries
Nr. of Employees
small (1-50)
Avirmax Biopharma Inc
Patents
Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses
US-11898178-B2
View DetailsCatalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses
US-11453869-B2
View Details
Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses
US-11898178-B2
View DetailsCatalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses
US-11453869-B2
View DetailsProducts
Clinical-grade rAAV vector supply
Manufacture and supply of GMP-grade rAAV vectors intended for use in clinical investigations.
Clinical-grade rAAV vector supply
Manufacture and supply of GMP-grade rAAV vectors intended for use in clinical investigations.
Services
End-to-end manufacturing services for rAAV vectors including process development, scale-up, purification, characterization and supply of material for clinical investigation.
Research-grade production of rAAV vectors and plasmid DNA for preclinical testing and development use.
Research and development services for capsid design, vector optimization and preclinical candidate generation focused on ocular gene therapeutics.
Transfer of manufacturing processes, documentation and know‑how to external partners and customers to enable production and scale-up of AAV-based genetic medicines.
End-to-end manufacturing services for rAAV vectors including process development, scale-up, purification, characterization and supply of material for clinical investigation.
Research-grade production of rAAV vectors and plasmid DNA for preclinical testing and development use.
Research and development services for capsid design, vector optimization and preclinical candidate generation focused on ocular gene therapeutics.
Transfer of manufacturing processes, documentation and know‑how to external partners and customers to enable production and scale-up of AAV-based genetic medicines.
Expertise Areas
- rAAV vector engineering
- AAV capsid engineering
- Gene expression optimization for viral vectors
- rAAV manufacturing and CMC
Key Technologies
- Recombinant AAV (rAAV) vectors
- Capsid engineering
- Gene-of-interest expression enhancement
- Baculovirus-based production systems